Drugs / RTL1000
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00411723 | Dec 2006 → Feb 2009 | chronic progressive multiple sclerosis, relapsing-remitting multiple sclerosis | Artielle ImmunoTherapeutics | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTL1000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00411723 ↗ |
| Modality | Protein / enzyme biologic | “RTL1000 (recombinant T cell receptor ligand)” NCT00411723 ↗ |
| Route | Intravenous | “single intravenous dose of RTL1000” NCT00411723 ↗ |